STAT+: PhRMA execs paint grim picture of industry under Medicare drug price negotiation
PhRMA on Wednesday painted a grim picture for the future of drug development under Medicare price negotiation. But others say the sector is fearmongering.
WASHINGTON — Executives for the brand drug industry’s biggest lobbying group painted a grim picture for the future of drug development under Medicare price negotiation. But others say the sector is fearmongering.
Medicare last month provided details for how it will choose which drugs will be subject to price negotiation, and how it will calculate the government’s opening offers.
What's Your Reaction?
